Acadia Pharmaceuticals Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $177.7M | $319.6M | $188.7M | $114.8M | $147.4M | $326.0M | $189.7M | $134.8M |
| Accounts Receivable | $121.5M | $98.7M | $98.3M | $62.2M | $64.4M | $48.2M | $35.8M | $26.1M |
| Inventory | $111.4M | $91.7M | $40.4M | $11.6M | $14.1M | $9.7M | $6.3M | $4.1M |
| Total Current Assets | $1.06B | $938.3M | $616.1M | $507.9M | $617.8M | $717.6M | $760.3M | $526.1M |
| Property, Plant & Equipment | $7.5M | $4.2M | $4.6M | $6.0M | $8.0M | $9.2M | $3.2M | $3.3M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | $108.9M | $119.8M | $65.5M | $0 | $0 | $1.1M | $2.6M | $4.1M |
| Total Assets | $1.56B | $1.19B | $749.0M | $587.8M | $700.1M | $782.6M | $783.2M | $540.2M |
| Liabilities | ||||||||
| Accounts Payable | $10.9M | $16.2M | $17.5M | $12.7M | $6.9M | $8.5M | $7.2M | $3.2M |
| Total Current Liabilities | $277.1M | $394.9M | $254.3M | $125.6M | $96.1M | $106.0M | $74.8M | $59.6M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $336.8M | $455.0M | $317.2M | $187.4M | $159.2M | $155.6M | $84.0M | $61.1M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-1.81B | $-2.20B | $-2.43B | $-2.37B | $-2.15B | $-1.99B | $-1.70B | $-1.47B |
| Total Stockholders' Equity | $1.23B | $732.8M | $431.8M | $400.4M | $540.9M | $627.0M | $699.1M | $479.1M |